Davita Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.84 (market cap $135.69M). The key difference: Davita Inc is far larger — about 83.2× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Davita Inc is more actively traded (582,204 versus 97,442). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and YieldMax AI & Tech Portfolio Option Income ETF for 61 Days on average.
| DVA | GPTY | |
|---|---|---|
Market Cap | $11.29B | $135.69M |
Volume | 582,204 | 97,442 |
Sector | Health | Income / Options Overlay |
52-Week High | $240.96 | $50.52 |
52-Week Low | $103.87 | $34.73 |
Typical Hold Time | 114 Days | 61 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
GPTY trades at $42.84, down 0.76% with a bullish technical outlook from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.29-0.30, providing income generation. Recent coverage highlights the fund's AI-focused covered call strategy as offering high yield potential while retaining some upside participation in tech rallies.
The outlook remains positive for income-seeking investors, with the options-based strategy generating substantial distributions. Key risks include market volatility impacting the underlying AI portfolio and the trade-off between income generation and capital appreciation potential in strong bull markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →